Diabetes
-
Who benefits from over-the-counter CGMs?
Experts speaking at the ADA’s Scientific Sessions supported making CGMs more accessible, but debated their usefulness for adults without diabetes.
By Elise Reuter • July 1, 2025 -
New glucose sensors, insulin patch pumps lead ADA’s Scientific Sessions
The diabetes conference featured a debate about over-the-counter glucose monitors and updates on upcoming devices, including insulin patch pumps. Here’s a roundup of MedTech Dive’s coverage.
By Elise Reuter • July 1, 2025 -
Tandem’s Elizabeth Gasser on patch pump plans, Abbott partnership
The strategy and product exec said Tandem aims to give patients options and reach more people who haven’t yet used insulin pumps.
By Elise Reuter • June 25, 2025 -
ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors
Medtronic, Beta Bionics and Tandem Diabetes Care showcased planned patch pumps at the conference, while Senseonics shared updates on its implantable glucose sensors.
By Elise Reuter • June 24, 2025 -
Insulet’s Eric Benjamin shares update on automated insulin delivery system
The chief product and customer experience officer said Insulet has seen an uptick in users with Type 2 diabetes since receiving an expanded indication, and shared an update on plans for a closed-loop system.
By Elise Reuter • June 23, 2025 -
5 things to watch at the ADA’s Scientific Sessions
The American Diabetes Association’s annual conference kicks off amid a dynamic year for diabetes tech, as access improves for people with Type 2 diabetes and companies debut new devices.
By Elise Reuter • June 20, 2025 -
Dexcom recalls more than 700,000 CGM receivers for lack of audible alarm
Severe adverse events, including seizure and loss of consciousness, were potentially linked to the issue, based on 56 reports Dexcom received.
By Elise Reuter • Updated June 24, 2025 -
Q&A
Abbott’s new diabetes leader on latest sensors, partnerships and Type 2 coverage
Ahead of the American Diabetes Association’s Scientific Sessions, Chris Scoggins said Abbott’s ambition is to be the most broadly connected diabetes tech company.
By Elise Reuter • June 12, 2025 -
Tandem, Abbott team on insulin delivery with glucose-ketone sensor
Tandem will integrate its insulin delivery systems with a new dual glucose-ketone sensor being developed by Abbott.
By Elise Reuter • June 10, 2025 -
Owens & Minor spikes $1.36B Rotech buyout over regulatory barriers
The companies scrapped the merger because securing FTC clearance “proved unviable in terms of time, expense and opportunity.”
By Nick Paul Taylor • June 6, 2025 -
Q&A
Beta Bionics CEO, CFO on how to take a company public
CEO Sean Saint and CFO Stephen Feider spoke about what’s different now that the company is public and the long journey of pursuing an IPO.
By Ricky Zipp • June 2, 2025 -
Why Medtronic plans to spin out its diabetes business
While some analysts questioned why Medtronic would leave a fast-growing market, others backed the company’s plan to focus on segments with higher margins.
By Elise Reuter • May 22, 2025 -
Medtronic plans to spin off diabetes business within 18 months
CEO Geoff Martha told investors the split simplifies Medtronic’s portfolio, while creating a stand-alone diabetes tech competitor.
By Ricky Zipp • May 21, 2025 -
Dexcom CEO says CGMs fit MAHA agenda ‘very nicely’; Tandem preps for new products
In earnings calls, diabetes tech companies had less to say about tariffs and focused more on future growth.
By Elise Reuter • May 16, 2025 -
Embecta restructures again, outlines tariff costs
The diabetes tech company announced a second restructuring after ending its insulin patch-pump program.
By Elise Reuter • May 13, 2025 -
Roche plans $550M expansion of Indianapolis site to manufacture CGMs
Roche Diagnostics plans to produce glucose monitors at the site within three years and prepare for future generations of its sensors.
By Elise Reuter • May 12, 2025 -
New Insulet CEO Ashley McEvoy sets priorities
The diabetes tech company raised its expectations for revenue and gross margins, despite the impact of tariffs.
By Elise Reuter • May 9, 2025 -
Q&A
ADA’s Osagie Ebekozien on diabetes tech for Type 2, new CGM standards
Ebekozien, chief quality officer of the American Diabetes Association, said the nonprofit is seeing a shift with more devices authorized for Type 2 diabetes.
By Elise Reuter • May 9, 2025 -
Abbott integrates diabetes data into Epic’s electronic health records
Linking the systems will allow clinicians to view glucose data captured by Libre glucose sensors within Epic’s systems.
By Nick Paul Taylor • May 1, 2025 -
Senseonics, Sequel partner to use 1-year CGM in automated insulin dosing system
The partnership extends the compatibility of Sequel’s Twiist system to allow people with Type 1 diabetes to pair the device with Senseonics’ Eversense 365 CGM.
By Nick Paul Taylor • April 30, 2025 -
Ashley McEvoy named Insulet CEO
McEvoy, the former leader of Johnson & Johnson’s medtech business, started immediately. Jim Hollingshead, who was CEO of Insulet for three years, resigned on Monday but will work as a consultant.
By Elise Reuter • April 28, 2025 -
Medtronic seeks FDA nod for insulin pump, furthering Abbott collab
Receiving FDA clearance would allow Medtronic to pair its pumps with a glucose monitor being developed for the company by Abbott.
By Elise Reuter • April 24, 2025 -
Medtronic gets FDA approval to use Simplera Sync glucose sensor with insulin pumps
The updated device allows users to pair the sensor with Medtronic’s insulin pumps, and is expected to grow the company’s diabetes business.
By Elise Reuter • April 21, 2025 -
Illumina, Tempus AI partner to drive genomic testing beyond cancer
The partners plan to build evidence packages that standardize comprehensive genomic profiling and other molecular testing across all major diseases.
By Nick Paul Taylor • April 18, 2025 -
Dexcom nets FDA clearance for 15-day CGM
The longer wear time should improve Dexcom’s margins and help it compete with Abbott, RBC Capital Markets analyst Shagun Singh said.
By Elise Reuter • April 10, 2025